This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws (collectively, “Forward-looking Statements”). Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. In August 2021, Ginkgo and Cronos announced the achievement of its first equity milestone for cannabigerolic acid (CBGA). Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact. GINKGO BIOWORKS INVESTOR CONTACT: investors@ginkgobioworks.com GINKGO BIOWORKS MEDIA CONTACT: press@ginkgobioworks.com Forward-looking Statements of Cronos Group Inc.
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access...
Read the full article @ Marijuana Stocks